1. Home
  2. TPST vs GBIO Comparison

TPST vs GBIO Comparison

Compare TPST & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPST
  • GBIO
  • Stock Information
  • Founded
  • TPST 2011
  • GBIO 2016
  • Country
  • TPST United States
  • GBIO United States
  • Employees
  • TPST N/A
  • GBIO N/A
  • Industry
  • TPST Biotechnology: Pharmaceutical Preparations
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TPST Health Care
  • GBIO Health Care
  • Exchange
  • TPST Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • TPST 33.0M
  • GBIO 29.5M
  • IPO Year
  • TPST N/A
  • GBIO 2020
  • Fundamental
  • Price
  • TPST $7.71
  • GBIO $4.40
  • Analyst Decision
  • TPST Hold
  • GBIO Strong Buy
  • Analyst Count
  • TPST 3
  • GBIO 4
  • Target Price
  • TPST $30.00
  • GBIO $73.33
  • AVG Volume (30 Days)
  • TPST 94.5K
  • GBIO 210.2K
  • Earning Date
  • TPST 08-07-2025
  • GBIO 08-06-2025
  • Dividend Yield
  • TPST N/A
  • GBIO N/A
  • EPS Growth
  • TPST N/A
  • GBIO N/A
  • EPS
  • TPST N/A
  • GBIO N/A
  • Revenue
  • TPST N/A
  • GBIO $24,556,000.00
  • Revenue This Year
  • TPST N/A
  • GBIO N/A
  • Revenue Next Year
  • TPST N/A
  • GBIO N/A
  • P/E Ratio
  • TPST N/A
  • GBIO N/A
  • Revenue Growth
  • TPST N/A
  • GBIO 146.47
  • 52 Week Low
  • TPST $5.35
  • GBIO $3.00
  • 52 Week High
  • TPST $28.34
  • GBIO $35.80
  • Technical
  • Relative Strength Index (RSI)
  • TPST 59.30
  • GBIO 53.21
  • Support Level
  • TPST $7.13
  • GBIO $4.28
  • Resistance Level
  • TPST $8.75
  • GBIO $5.10
  • Average True Range (ATR)
  • TPST 0.45
  • GBIO 0.62
  • MACD
  • TPST 0.13
  • GBIO 0.01
  • Stochastic Oscillator
  • TPST 63.83
  • GBIO 30.16

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: